Olivier Legrain

Across three decades at the helm of IBA, Olivier Legrain returns again and again to a single conviction: that a company's real measure is not its balance sheet but the difference it makes in people's lives. He frames his own tenure in personal, almost familial terms, writing that he has "a zillion reasons to be proud to serve IBA for 30 years" , and marking IBA's fortieth anniversary as a moment "celebrating 40 years of IBA" that "reminded me that our mission is only possible because of the people behi[nd it]" . This recurring vocabulary of pride and gratitude is not incidental; it signals how closely Legrain ties corporate milestones to a sense of collective purpose rather than individual achievement, whether he is congratulating a partner institution or a colleague's project .

That sense of purpose is made explicit in his L'Echo podcast appearance, where he argues that a company's mission extends well beyond short-term profit maximization and must account for its responsibility toward employees, society and the environment, and that building in medium and long-term thinking, rather than fixating on stock price, lets a business manage risk better, attract talent, and create value for stakeholders while still turning a profit ¹⁵. This is the theoretical backbone for much of what he says elsewhere about IBA's projects: technology and commercial success are treated as means to a broader end, not ends in themselves.

That end, for Legrain, is most vividly expressed through IBA's work on humanizing cancer care. He describes the Oncia Community as "the ultimate incarnation of IBA commitment to 'Care' on a global scale," adding that "it represents our realization that technology alone isn't enough" . In a French-language post about the Maison Mieux Être, he invokes Maggie Jenks, the inspiration behind England's Maggie's Centres, quoting her belief in not losing "la joie de vivre dans la peur de mourir," and states plainly that "nous avons l'obligation morale d'accélérer le développement de ce type de maison" . He returns to this same register when describing another cancer-care initiative as "one of the most important innovation in cancer care," restating that he is "proud to be part of this unbelievable adventure" . Taken together, these statements show a consistent argument: clinical and technical excellence must be paired with emotional and psychological support, and Legrain treats this pairing as a moral obligation for IBA rather than a marketing add-on.

Legrain is equally deliberate when discussing how IBA is governed as it grows. Announcing a reshuffle of the executive team, he explains that expanding the responsibilities of Henri de Romrée as Deputy CEO and Catherine Vandenborre as Chief Ventures & Corporate Officer is meant "to support our next chapter of growth and innovation," while his own move allows him "to focus deeply on the strategic steering of the Group" and his added role as Vice-Chairman is designed "to create an even closer, more agile link between our leadership team and our shareholder representatives" . He closes that announcement with "I have absolute confidence in Henri, Catherine, and the entire team," underscoring a leadership style built on delegation and trust rather than centralization .

Internationally, Legrain consistently frames IBA's growth through the lens of partnership and access rather than market expansion for its own sake. He highlights the commissioning of a new Cyclone-18 cyclotron with Kazakhstan's Institute of Nuclear Physics as a project that "will significantly boost Kazakhstan's nuclear medicine capacity, ensuring uninterrupted access to advanced, life-saving cancer diagnostics," thanking partners "for your continued trust in IBA" . Similar language recurs around Moffitt Cancer Center and Houston, where he simply notes, "At IBA we have great customers. Thank you Houston" . He also values the communities that form around these technologies, calling one gathering of proton therapy specialists "a vibrant community" and describing the honor of hosting "such a group of luminaries delivering the promise of Proton Therapy to thousands of patients around the world" .

This emphasis on community extends into how Legrain talks about professional gatherings more broadly. In his Amstro interview, he praises the value of a small, high-quality conference precisely because it enables "quality interactions with interesting people and sessions," and argues that such conferences build community among practitioners, which in turn "enable[s] faster learning, knowledge sharing, and quicker adoption of best practices in radiation oncology" ¹⁶. This is consistent with his broader belief, stated in the L'Echo podcast, that value creation is a collective, stakeholder-driven process rather than a purely competitive one ¹⁵.

Finally, Legrain treats innovation itself as inseparable from accessibility and sustainability. Introducing the Rhodotron® LITE, he states that "innovation is only meaningful if it drives positive impact," and describes the product as enhancing accessibility, driving sustainability, and meeting evolving market needs "without comprom[ise]" . The concrete takeaway from Legrain's public statements is a fairly unified worldview: technology should widen access to care rather than restrict it, corporate governance should distribute responsibility rather than concentrate it, and a company's long-term legitimacy rests on its willingness